APRE · Aprea Therapeutics, Inc.
$0.62
+0.01 (+1.19%)
At close · Jul 29
Going-concern doubt
— flagged May 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern.”View the 10-Q filed May 13, 2026
Market Cap
$7.60M
Shares
12.38M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Christian S. Schade | CEO | $3,677,567 |
| Scott M. Coiante | CFO | $1,809,419 |
| Eyal C. Attar | Senior Vice President, Chief Medical Officer | $1,189,283 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Christian S. Schade | CEO | $593,280 |